secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001493152-23-010438
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte reports FY2022 revenue $5.6M (-27%); plans to extend 10-K filing
-------------------------------------------------------------------------

- FY2022 revenue $5.6M (down 27% YoY); Q4 revenue $1.1M (down 69% YoY).
- DetermaRx revenue FY2022 $3.6M (+47% YoY); Q4 $0.8M (+3% YoY).
- Consolidated operating expenses $69.0M including $44.6M impairment loss; continuing ops revenue $1.0M.
- Plans to file Form 12b-25 to extend 10-K deadline to April 17, 2023.
- Cost reduction targets quarterly cash burn below $6M in H2 2023 (from $10.5M in H2 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/0001493152-23-010438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer